-The Economic Times To ensure access to healthcare for all, India must harness innovation in discovering drugs, in developing therapeutics and in delivering affordable healthcare. It is in the light of these facts that one should evaluate the impact of the Indian Supreme Court's ruling in the case involving patent protection for Novartis AG's cancer drug, Glivec. Glivec was the first-of-its-kind cancer drug for leukaemia patients with patent protection in nearly 40...
More »SEARCH RESULT
Calling big pharma’s bluff -Dwijen Rangnekar
-The Hindu The lesson from the Supreme Court ruling on Gleevec is that pharmaceutical multinational corporations need to focus research on genuine innovations rather than on ways to evergreen their patents The much awaited Supreme Court judgment on Gleevec has been delivered. Novartis has failed in reversing the rejection of its patent. And, predictably - like a scratched record - there have been suggestions that pharma investments in India will dry...
More »When innovation is under threat-Swati Piramal
-The Financial Express A patent law that is transparent, based on principles of good science & encourages innovation is in India's interest In 500 BC, in the Greek city of Sybaris, it was proclaimed that "encouragement was held out to all who should discover any new refinement in luxury, the profits arising from which were secured to the inventor by patent for the space of a year." England followed with the Statute...
More »In Bastar, CRPF launches a soft offensive to win over villagers-Suvojit Bagchi
-The Hindu It joins hands with AIIMS to offer health services to villagers Raipur: Maoists as well as security forces have hit upon new strategies to gain an upper hand in the ongoing conflict. The latest one - to check the influence of rebels - has come from the Central Reserve Police Force (CRPF). It is not at all a military manoeuvre, but an offer of medical assistance to villagers in the Maoist-controlled...
More »Novartis order may force pharma MNCs to change
-The Economic Times Foreign pharma Companies could be forced to overhaul their strategy for the Indian market by striking more local deals and cutting sky-high drug prices after the Supreme Court slammed the door on Swiss giant Novartis' attempts to gain a patent for its blood cancer-busting drug Glivec. But the ruling, welcomed by activists campaigning for affordable drugs and local generic Companies, threatened to reinforce a narrative that India...
More »